Proactive Investors - Run By Investors For Investors

MaxCyte teams up with American gene editing specialist to develop new generation of cancer treatments

The company has partnered with Precision Biosciences of the US
MaxCyte teams up with American gene editing specialist to develop new generation of cancer treatments
MaxCyte's new partner has developed the ARCUS gene editing platform

MaxCyte PLC (LON:MXCT) has negotiated a clinical and commercial licence deal with Precision Biosciences of the US.

Under the terms of the agreement, Precision will use MaxCyte's flow electroporation cell engineering technology alongside its own ARCUS genome-editing platform.  

The plan is to develop the next generation of cell-based therapies for cancer.

READ: MaxCyte inks research agreement with Gilead subsidiary Kite Pharma​

"Precision's therapeutic grade ARCUS editing platform is sufficiently compact and specific to use with a range of delivery systems,” said its chief development officer David Thomson.

“In considering these, we have found MaxCyte's electroporation technology complements our approach to allogeneic T cell manufacturing, which is focused on preserving cell quality throughout the process while maximising overall yield."

Building on earlier deal 

The new tie-up builds on a research and clinical licence agreement the two already had. Under the new terms, MaxCyte will receive undisclosed milestone payments and technology access licensing fees.

"The initiation of this commercial license agreement with Precision, a leader in genome editing with its own proprietary ARCUS technology, signifies a key milestone for MaxCyte and demonstrates the value and versatility of our platform, our intellectual property, and our ability to foster important collaborations with companies generating life-changing gene therapies," said MaxCyte chief executive Doug Doerfler.

The AIM-listed life sciences group’s flow electroporation technology allows cells to be re-engineered efficiently, with high viability and recovery.

Precision will use its ARCUS gene editing tools and the MaxCyte’s breakthrough to transform donor cells into immunotherapies such CAR-T cells.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018

Related Articles

1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use